Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent ...
Study Results Position Company to Target Segments of $270B+ Multi-Billion Dollar Drug Delivery Systems Market 1 VANCOUVER, BC, Oct. 31, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (BVAXF) ...
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against ...
EnerSys ® ENS, the global leader in stored energy solutions for industrial applications, today announced the launch of its DPX Distributed Power Transport System featuring the company's new EnShield™ ...
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results